Infinity Pharmaceuticals (NASDAQ:INFI – Get Rating) is scheduled to be posting its quarterly earnings results before the market opens on Monday, November 14th. Analysts expect Infinity Pharmaceuticals to post earnings of ($0.05) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.
Infinity Pharmaceuticals (NASDAQ:INFI – Get Rating) last posted its earnings results on Tuesday, August 9th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.01. Infinity Pharmaceuticals had a negative return on equity of 299.00% and a negative net margin of 2,110.33%. The company had revenue of $0.69 million for the quarter, compared to the consensus estimate of $0.68 million. On average, analysts expect Infinity Pharmaceuticals to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Infinity Pharmaceuticals Stock Performance
INFI stock opened at $1.19 on Friday. Infinity Pharmaceuticals has a fifty-two week low of $0.46 and a fifty-two week high of $2.81. The business’s 50-day moving average is $1.23 and its two-hundred day moving average is $0.97. The company has a market cap of $106.24 million, a price-to-earnings ratio of -2.29 and a beta of 1.40.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
Separately, StockNews.com initiated coverage on Infinity Pharmaceuticals in a report on Wednesday, October 12th. They issued a “hold” rating on the stock.
Infinity Pharmaceuticals Company Profile
Infinity Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors.
- Get a free copy of the StockNews.com research report on Infinity Pharmaceuticals (INFI)
- MarketBeat: Week in Review 11/7 – 11/11
- Oil Is a Compelling Reason The Sell-Off In Stocks Isn’t Over
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don’t Want to Get Stuck On
- Vision Hydrogen, Now Vision Energy, Puts Hopes In Stock Split
Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.